Cargando…

Admission respiratory status predicts mortality in COVID‐19

COVID‐19 has significant case fatality. Glucocorticoids are the only treatment shown to improve survival, but only among patients requiring supplemental oxygen. WHO advises patients to seek medical care for “trouble breathing,” but hypoxemic patients frequently have no respiratory symptoms. Our coho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Neal A., Jensen, Paul N., Harris, Andrew W., Nguyen, Daniel D., Huang, Henry D., Cheng, Richard K., Savla, Jainy J., Larsen, Timothy R., Gomez, Joanne Michelle D., Du‐Fay‐de‐Lavallaz, Jeanne M., Lemaitre, Rozenn N., McKnight, Barbara, Gharib, Sina A., Sotoodehnia, Nona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242415/
https://www.ncbi.nlm.nih.gov/pubmed/34028169
http://dx.doi.org/10.1111/irv.12869
Descripción
Sumario:COVID‐19 has significant case fatality. Glucocorticoids are the only treatment shown to improve survival, but only among patients requiring supplemental oxygen. WHO advises patients to seek medical care for “trouble breathing,” but hypoxemic patients frequently have no respiratory symptoms. Our cohort study of hospitalized COVID‐19 patients shows that respiratory symptoms are uncommon and not associated with mortality. By contrast, objective signs of respiratory compromise—oxygen saturation and respiratory rate—are associated with markedly elevated mortality. Our findings support expanding guidelines to include at‐home assessment of oxygen saturation and respiratory rate in order to expedite life‐saving treatments patients to high‐risk COVID‐19 patients.